Skip to main content
Premium Trial:

Request an Annual Quote

Luminex's Revenues Rise, Loss Tumbles in Second Quarter

NEW YORK (GenomeWeb news) – Luminex reported after the close of the market on Thursday that its second-quarter revenues jumped 38.7 percent and its net loss fell 92 percent year over year.
The Austin, Texas-based diagnostics instrumentation and assay developer brought in revenues of $24.3 million for the three-month period ended June 30, compared to revenues of $17.5 million for the second quarter of 2007. Sales for its technology group increased to $20.3 million from $13.6 million, and sales for its assay group inched up to $4.1 million from $4 million.
The firm noted that it shipped 203 of its xMAP systems during the quarter, bringing the total number of shipments for the instrument to date to 5,402.
Luminex’s net loss dropped sharply to $1 million, or $.03 per share, from $12.1 million, or $.34 per share, in the comparable quarter of 2007. The 2007 results include $8 million in charges for in-process research and development.
The firm’s R&D spending increased 28.2 percent to $5 million from $3.9 million, and its SG&A expenses climbed 13.1 percent to $12.1 million from $10.7 million.
Luminex finished the quarter with $102.7 million in cash. During the second quarter, the firm raised $74.3 million in a public offering of 4,025,000 shares of common stock.
Luminex reaffirmed its full-year 2008 revenue guidance of between $95 million and $105 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more